Impact Of DRGs On Clinical Research Less Than First Feared, Speakers Tell NIH Directors Meeting
In Brief: Calabresi Named DCT Board Chairman; NCI Gets $5 Million Gifts for Intramural Breast Cancer Work
Organ Systems Program Finally Loses a Couple, But Gets OK for Breast Cancer Risk Study RFA
Other Concepts Approves By DCE Board Last Week
New Cancer Education Program “Striking Change,” To Fund CR, Prebaccalaureate, Summer Training
Adamson Rips “Rip Van Bailer”
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
